2028, date not disclosed
Tecentriq expected to lose US exclusivity
Patent-expiry estimate. The 12-year US biologic exclusivity ends in May 2028. Roche does not publish Tecentriq's patent dates, which may run later. Sales CHF 3.57B.
When does Tecentriq go off patent?
In the US, biosimilars can launch from 2028. Tecentriq is sold by Roche. The 12-year US biologic exclusivity ends in May 2028. Roche does not publish Tecentriq's patent dates, which may run later. Sales CHF 3.57B.
Tecentriq's US exclusivity date is based on patent-expiry estimate. It is estimated from patent expiry rather than a fixed entry date, so it may move as patents are challenged or extended. It is a biologic, so copies are biosimilars. Biosimilars are harder to make and usually erode sales more gradually than generics.
No US filing found No Tecentriq biosimilar is approved, and we found no program in late-stage US development as of October 2026.
Checked October 2026. Sources: FDA Purple Book
Patent-expiry estimate. The 12-year US biologic exclusivity ends in May 2028. Roche does not publish Tecentriq's patent dates, which may run later. Sales CHF 3.57B.
Among past biologics facing biosimilars: Humira's US sales fell to 65% of their 2022 level in its first full year of biosimilars (2023) and 16% two years later; Stelara's US sales fell to 57% of their 2024 level in its first full year of biosimilars (2025). See how past cliffs played out →
Tecentriq is 5.8% of Roche's 2025 revenue (≈$4.3B of $74.1B). With Xolair, Perjeta, Ocrevus and Vabysmo, the drugs tracked here add up to 34% of Roche's revenue losing US exclusivity by 2034. Group sales CHF 61.5B, including Diagnostics.
Bars show each company's tracked drugs as a share of its total 2025 revenue. Tecentriq is highlighted.